RT @NEJM: #ASH18 Weekend Roundup: Hydroxyurea in African Children with Sickle Cell Disease (REACH) https://t.co/1AieOhYqP0 Ibrutinib Regi…
RT @NEJM: #ASH18 Weekend Roundup: Hydroxyurea in African Children with Sickle Cell Disease (REACH) https://t.co/1AieOhYqP0 Ibrutinib Regi…
RT @NEJM: #ASH18 Weekend Roundup: Hydroxyurea in African Children with Sickle Cell Disease (REACH) https://t.co/1AieOhYqP0 Ibrutinib Regi…
RT @gonen_mithat: An example of immortal time bias? If you are a complete responder you must have a lived a minimum amount of time which ex…
RT @NEJM: #ASH18 Weekend Roundup: Hydroxyurea in African Children with Sickle Cell Disease (REACH) https://t.co/1AieOhYqP0 Ibrutinib Regi…
#ASH18 Weekend Roundup: Hydroxyurea in African Children with Sickle Cell Disease (REACH) https://t.co/1AieOhYqP0 Ibrutinib Regimens vs. Chemoimmunotherapy in CLL https://t.co/JRmHNWSxcX Tisagenlecleucel in Large B-Cell Lymphoma (JULIET) https://t.co/4uz
RT @gonen_mithat: An example of immortal time bias? If you are a complete responder you must have a lived a minimum amount of time which ex…
An example of immortal time bias? If you are a complete responder you must have a lived a minimum amount of time which explains away the long flat region at the beginning and the difference between the two curves at, say, 2 months is just about the same as
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/Yw73n9x9zM
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
RT @_jdevos_: Given the costs of CART treatment, an intention to treat analysis is of paramount importance. https://t.co/oy23CmVHFp
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/seGq4MQ19k
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
RT @kadsho: スタディ名称は誰かの “わがまま” ? (暴威...) https://t.co/Ryr9yx8yya
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/KAQlyzq6NV
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
#ASH18 | #Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | @NEJM | #leusm #lysm #ImmunoOnc #CAR-T https://t.co/ZwlUkmrE29
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/ViK5wjifWg #ASH18 https://t.co/lPypz8paUf
#Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell #Lymphoma | #NEJM https://t.co/8Gj6Ht434v
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
RT @SCTNB: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/QKVDn1psTf
Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/CewzuUBWzb #ASH18 https://t.co/CV7uXOfdts
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX…
Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/4uzijXERsX #ASH18 https://t.co/FsLbQtaYMy
RT @jq1234t: @bio_clouseau Except $NVS JULIET doesn’t use ITT. 30% of patients enrolled patients in JULIET excluded from efficacy analysis…
Absolutely incredible. These tiny details that the FDA is happy to overlook, eh $NVS #ASH18 https://t.co/dIGIhby9ey
RT @Sam_S_Kulkarni: Insightful chart. This is why we need to move allogeneic CAR-T’s as expeditiously as possible into the clinic! #ASH18 @…
Insightful chart. This is why we need to move allogeneic CAR-T’s as expeditiously as possible into the clinic! #ASH18 @CRISPRTX
Update: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/h7dOnWwd37
Given the costs of CART treatment, an intention to treat analysis is of paramount importance.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/8CdN1jELKq
CAR-T-cell therapy #tisagenlecleucel High/durable RFS in highly pretreated patients with DLBCL. @NEJM @ASH_hematology https://t.co/45ZS5jEQxp
RT @SCTNB: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/QKVDn1psTf
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/QKVDn1psTf
RT @Haem_pmcc_rmh: GREAT to see the pivotal NEJM paper showing #cart #kymriah is active in #DLBCL. Congrats Dr Tam and colleagues! Massive…
What's the reason for it ? To mislead us?
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/pTEJNX3SJL
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (JULIET) https://t.co/mpEFC9BBXg
GREAT to see the pivotal NEJM paper showing #cart #kymriah is active in #DLBCL. Congrats Dr Tam and colleagues! Massive contribution from trials team at Peter Mac a few years ago https://t.co/yGf5UJ1kEp #lymsm #ASH18 #lymphoma @haem_pmcc_rmh @TheRMH @lym
RT @DrRaulCordoba: #Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell #Lymphoma | NEJM #CART #lymsm https://t.co/1EMX6…
RT @VPplenarysesh: CAR-T trials continue to be hard to interpret because they do not use the intention to treat denominator of pts who enro…
RT @Alahmari_MD: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/XF3RbuKQgD
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM Just on time for ASH .... https://t.co/WkTPEOprH4
A 40% complete response rate is not THAT great considering the incredible price of this treatment. Risk sharing with @Novartis must be sought! Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/qPEd6OURSr
RT @HugoZH: @sesiegler icymi https://t.co/wEiMKowfVc
RT @Alahmari_MD: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/XF3RbuKQgD
RT @DrRaulCordoba: #Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell #Lymphoma | NEJM #CART #lymsm https://t.co/1EMX6…
@sesiegler icymi
Has nobody heard of reporting by intention to treat? #ASH2018 #nejm #lymphoma https://t.co/09qRCegfiH
food for thought as our institution roles out CAR-T
RT @FayCortez: A peek at duration of benefit with Novartis' Kymriah in DLBCL. More data coming later at #ASH18. Tisagenlecleucel in Adult R…
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/XF3RbuKQgD
A peek at duration of benefit with Novartis' Kymriah in DLBCL. More data coming later at #ASH18. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/QZfscv1Ziw
.@bccww additional info on CAR T
RT @DrRaulCordoba: #Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell #Lymphoma | NEJM #CART #lymsm https://t.co/1EMX6…